(Adj) Professor Theo Kofidis advocates for the widespread adoption of minimally invasive mitral valve surgery…
(Adj) Professor Theo Kofidis, leading a team at the National University Health System (NUHS) in Singapore, spearheaded the development of SingValve, a groundbreaking mitral valve bioprosthesis. This innovative implant, designed to mimic the natural human mitral valve, addresses the limitations of current artificial valves by offering flexibility and customization based on individual patient needs. Under his leadership, Singvalve has received significant funding from the NRF Central Gap Fund to advance through rigorous testing and validation stages, aiming for first-in human trials by 2023. (Adj) Professor Kofidis emphasises Singvalve’s potential to set new standards in cardiac surgery, positioning Singapore ας a hub for cutting-edge medical technology and innovation.

